Allarity Therapeutics, Inc. (ALLR)
ALLR Stock Price Chart
Explore Allarity Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ALLR price movements and trends.
ALLR Company Profile
Discover essential business fundamentals and corporate details for Allarity Therapeutics, Inc. (ALLR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Dec 2021
Employees
6.00
Website
https://www.allarity.comCEO
Thomas H. Jensen
Description
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
ALLR Financial Timeline
Browse a chronological timeline of Allarity Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 21 Aug 2026
EPS estimate is -$0.25, while revenue estimate is $25.00k.
Earnings released on 15 May 2026
EPS came in at -$0.17 surpassing the estimated -$0.22 by +22.73%, while revenue for the quarter reached $25.00k , meeting expectations.
Earnings released on 31 Mar 2026
EPS came in at -$0.19 surpassing the estimated -$0.22 by +13.64%, while revenue for the quarter reached $320.00k , meeting expectations.
Earnings released on 14 Nov 2025
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%.
Earnings released on 15 Aug 2025
EPS came in at -$0.15 surpassing the estimated -$0.21 by +28.57%.
Earnings released on 9 May 2025
EPS came in at -$0.25 .
Earnings released on 4 Apr 2025
EPS came in at -$4.73 surpassing the estimated -$8.10 by +41.61%, while revenue for the quarter reached $6.00k .
Earnings released on 14 Nov 2024
EPS came in at -$7.71 surpassing the estimated -$8.52 by +9.51%.
Stock split effective on 11 Sept 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 Aug 2024
EPS came in at -$3.30 falling short of the estimated -$0.29 by -1.04k%.
Earnings released on 14 May 2024
EPS came in at -$664.86 falling short of the estimated -$1.76 by -37.68k%.
Earnings released on 29 Apr 2024
EPS came in at -$175.51 , while revenue for the quarter reached $112.00k .
Stock split effective on 9 Apr 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$1.35k falling short of the estimated -$8.17 by -16.37k%.
Earnings released on 14 Aug 2023
EPS came in at -$15.78k falling short of the estimated -$11.19 by -140.95k%.
Stock split effective on 29 Jun 2023
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at -$106.43k falling short of the estimated -$7.88 by -1.35m%.
Stock split effective on 27 Mar 2023
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Mar 2023
EPS came in at -$0.23 surpassing the estimated -$0.42 by +45.24%.
Earnings released on 14 Nov 2022
EPS came in at -$571.20k falling short of the estimated -$218.40k by -161.54%.
Earnings released on 7 Oct 2022
EPS came in at -$604.80k .
Earnings released on 27 May 2022
EPS came in at -$312.15k falling short of the estimated -$528.00 by -59.02k%.
Earnings released on 17 May 2022
EPS came in at -$2.14m .
Earnings released on 23 Nov 2021
EPS came in at $181.15k .
ALLR Stock Performance
Access detailed ALLR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
